Head-to-head evidence
ORMD-0801 vs SAR341402
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
ORMD-0801
Developed by Oramed
NCT04606576 · Phase 3 · terminated
This is a large, randomized, fully blinded, placebo-controlled trial using blood sugar control (A1C), the standard disease-defining measure for diabetes, as its primary endpoint, a well-designed setup for showing a real treatment effect. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: April 2027 · NCT06731075 (registry estimate)
SAR341402
Marketed by Sanofi
NCT03211858 · Phase 3 · completed
The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ORMD-0801's landscape · SAR341402's landscape